drugset / Trial / NCT06172387

Intra-arterial Albumin in Acute Ischemic Stroke After Endovascular Treatment for

NCT06172387

Phase 1 Unknown 46 enrolled Tianjin Huanhu Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Stroke is an acute focal injury of the central nervous system caused by cerebral vessels. One in every four people is affected by stroke at different times in life. Globally, stroke is the second leading cause of death and third leading cause of disability in adults. we hypothesized that in patients with acute large vessel occlusive ischemic stroke treated with mechanical thrombectomy, the infusion of 20% human serum albumin solution into the revascularization area can exert a stronger neuroprotective effect.

Timeline

Start
2023-11-01
Primary completion
2024-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Albumin Protein / enzyme biologic 0.6 g/kg Other

Indications